Pralatrexate

Pralatrexate
	File:Pralatrexate.png
Identifiers
	IUPAC name N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl]; -3-butynyl]benzoyl]-L-glutamic acid;
CAS Number	146464-95-1;
PubChem CID	725808;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H23N7O5
Molar mass	477.47 g/mol

Pralatrexate (rINN), also known as 10-propargyl-10-deazaaminopterin, common name PDX, is a drug candidate being studied for the treatment of cancer. PDX is a folate analog inhibitor of dihydrofolate reductase. As of July 2005, it is undergoing Phase 1 and Phase 2 clinical trials for treatment of non-Hodgkin lymphoma and non-small cell lung cancer.

External links

Identifiers
File:Pralatrexate.png
IUPAC name N-[4-[1-[(2,4-Diamino-6-pteridinyl)methyl] -3-butynyl]benzoyl]-L-glutamic acid
CAS Number	146464-95-1
PubChem CID	725808
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₃H₂₃N₇O₅
Molar mass	477.47 g/mol